Erschienen in:
23.09.2022 | Original Paper
Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?
verfasst von:
Eşay Kıran Yenice, Caner Kara
Erschienen in:
International Ophthalmology
|
Ausgabe 5/2023
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To investigate the relationship between the development of corrected 1-year-old refraction values and risk factors in preterm infants who underwent laser photocoagulation (LPC) therapy for retinopathy of prematurity (ROP).
Methods
The ophthalmic examination findings of preterm neonates who had developed Type I ROP and received LPC therapy were evaluated retrospectively. The association between spherical equivalent (SE) values and clinical findings were analyzed by using multivariable linear regression analysis.
Results
The study included 157 eyes of 80 neonates with a mean birth week of 27.1 ± 2.2 weeks (23 to 32 weeks) and a mean birth weight of 995 ± 273 g (565 to 1760 g). The treatments were administered on an average of 36.8 ± 2.7 (32 to 45 weeks) postmenstrual age. LPC treatment was applied bilaterally to 77 of the 80 neonates included in the study, and unilaterally to 3 of them. The mean ± standard deviation of the SE value was 0.31 ± 1.89 diopters (D) (− 8.00 to 4.63 D) according to the results of the 1-year corrected age refraction examination. In univariate analysis, no significant association between GA, BW, and ROP zone and SE value, while the number of laser spots (ß = − 0.27 ± 0.00 D, p = 0.00) and stage 3 ROP (ß = − 0.29 ± 0.37 D, p = 0.00) were significantly associated with the SE value. In multivariable linear regression analysis, a significant association between number of laser spot, stage 3 ROP and SE value (ß = − 0.25 ± 0.00 D, p = 0.01 for number of laser spot, ß = − 0.28 ± 0.36 D, p = 0.00 for stage 3 ROP).
Conclusion
In conclusion, this study supports that stage of ROP and the number of laser spots count applied in photocoagulation treatment for ROP is significantly correlated with degree of myopia (p < 0.05).